The Effect of a Single Dose of Quazepam (Sch-16134) on the Sleep of Chronic Insomniacs

  title={The Effect of a Single Dose of Quazepam (Sch-16134) on the Sleep of Chronic Insomniacs},
  author={Thomas Roth and E I Tietz and Milton Kramer and M Kaffeman},
  journal={Journal of International Medical Research},
  pages={583 - 587}
The present study evaluated the efficacy of 25 mg of quazepam, a new benzodiazepine hypnotic, in a population of chronic insomniacs. The results indicate that a single dose (25 mg) administered for one night was efficacious when measured both objectively by polysomnographic recording and subjectively by questionnaire with no reported side-effects. The change in the objective measures paralleled the direction of change in subjective measures. Sleep efficiency and sleep maintenance were improved… 

Figures and Tables from this paper

A Clinical Study of Quazepam in Hospitalized Patients with Insomnia
Quazepam demonstrated greater improvement in Hypnotic Activity Index and Sleep Quality Index from baseline scores, and caused no adverse reactions.
Evaluation of the Short-Term Treatment of Insomnia in Out-Patients with 15 Milligrams of Quazepam
It is demonstrated that quazepam, in a 15 mg dose, is an effective, rapidly acting, oral hypnotic agent with a low incidence of adverse effects.
Comparison of quazepam, flunitrazepam and placebo as single-dose hypnotics before surgery
SummaryThe hypnotic effect and tolerance of quazepam (Sch 16134) 15 and 30 mg, flunitrazepam 1 and 2 mg and placebo were evaluated in a one-night, randomized, double-blind, parallel group study of
Quazepam: Hypnotic Efficacy and Side Effects
  • A. Kales
  • Medicine, Psychology
  • 1990
Quazepam is a benzodiazepine hypnotic that can be useful in the adjunctive pharmacologic treatment of insomnia and is more effective with short‐term use, and with continued use it maintains its efficacy in contrast to both of these drugs which show rapid development of tolerance.
Comparison of the effects of quazepam and triazolam on cognitive-neuromotor performance
Performance scores were already showing recovery from peak impairment 2 h post-drug ingestion, although quazepam's potent N-desalkylflurazepAM metabolite has been found to maintain a maximum plateau level from 2 to 24 h.
Reintroduction of quazepam: an update on comparative hypnotic and adverse effects.
  • N. Moniri
  • Psychology, Biology
    International clinical psychopharmacology
  • 2019
The purpose of this review is to provide an update on distinguishing features of quazepam with regard to its pharmacology, pharmacokinetics, sleep efficacy and potential adverse effects compared to other agents used for insomnia.
Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia.
Overall, behavior therapy and pharmacotherapy produce similar short-term treatment outcomes in primary insomnia.
Manifestations and management of chronic insomnia in adults.
The Sleep in America Poll, conducted by the National Sleep Foundation, revealed that almost 50 percent of people surveyed had complaints of frequent insomnia, but only 6 percent were formally diagnosed.


The Effect of a New Benzodiazepine on the Polygraphically Monitored Sleep of Normal Volunteers
The subjective quality of sleep was improved by the new benzodiazepine hypnotic, and one subject reported that he felt lethargic the day after the largest dose.
The effect of a new benzodiazepine hypnotic on the polygraphically monitored sleep of normal volunteers
  • Journal of Clinical Pharmacology
  • 1977
Psychophysiological and biochemical changes following use and withdrawal of hypnotics
  • Sleep : Physiology and Pathology
  • 1969